DRUG
Somatuline Autogel (lanreotide acetate)
Injections
Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
Status
Completed
Phase
Phase 3
Enrollment
59
Locations
13
Results
Posted
Publications
1
Study summary
What the protocol is testing.
The purpose of this study is to determine whether subjects with acromegaly (or their partners) are able to self administer Somatuline Autogel at home.
Full detailed description
Clinical experience with Somatuline Autogel to date has raised the possibility of self or partner injection. Previous microparticle somatostatin analogue formulations required careful reconstitution and as a result the cost of the analogues and the inconvenience of reconstitution meant self or partner injection was not a viable option. Somatuline Autogel does not require reconstitution as it comes ready-mixed in a pre-filled syringe, thus making it more user-friendly than its predecessor and introducing the possibility of self or partner injection. Patients with acromegaly often travel considerable distances every 28 days in order to receive their somatostatin analogue injections in the clinic. If Somatuline Autogel can be safely administered unsupervised, while maintaining disease control, this could offer patients considerable benefits in terms of reduced frequency of visits to the clinic. This study is designed to allow suitably motivated patients with acromegaly or their partners to learn how to successfully inject Somatuline Autogel while maintaining their mean GH level control. Disease control in these patients will be assessed by comparing their GH and IGF-1 levels to accepted medical standards for control of acromegaly and by comparing the levels of GH and IGF-1 control achieved with baseline values.
Interventions
Treatment arms and agents.
BEHAVIORAL
Home administration
Questionnaire
Timeline
From registration to results.
First posted
Mar 14, 2007
Study start
Apr 2007
Primary completion
Dec 2008
Study completion
Dec 2008
Results posted
Dec 20, 2010
Registry updated
Nov 20, 2020
Outcomes
What the study measures.
Primary outcomes
The Percentage of Subjects or Their Partners That Are Competent to Self-administer Somatuline Autogel at the End of the Study, (Week 24/Early Termination), as Assessed by the Competence Questionnaire Score.
Time frame · 24 weeks
The primary efficacy endpoint was the percentage of patients (Switch and other) or their partners who were competent to self-administer lanreotide at the end of the study (Week 24/Early Termination), as assessed by the Assessment of Competence Questionnaire (0 = 'No' and 1 = 'Yes').
Secondary outcomes
Percentage of Switch Subjects Who Find Self-administration of Somatuline Autogel Convenient as Assessed by the Subject Convenience Questionnaire Score.
Time frame · 24 weeks
Experienced Convenience of Somatuline® Autogel® Injections was assessed by the subject as: Very convenient; somewhat convenient; neither convenient nor inconvenient; Neither convenient nor inconvenient; Somewhat inconvenient; very inconvenient.
Percentage of Switch Subjects That Have IGF-1 Levels Within the Normal Range for Age and Gender at the End of the Study
Time frame · 24 weeks
Blood sample was collected while subject is in a fasting state or non-fasting state for measuring the level of IGF-1.
Percentage of Switch Subjects That Have Glucose Suppressed GH Levels ≤ 2.5 ng/ml at the End of the Study, Week 24/Termination.
Time frame · 24 Weeks
Blood samples taken before and 60 and 120 min after glucose load from fasting patient.
Change of GH Concentration Levels From Basaeline to Week 24 in Switch Patients
Time frame · 24 Weeks
Blood samples taken before and 60 and 120 min after glucose load from fasting patient.
Total Symptom Questionnaire Score at Week 24/Termination
Time frame · 24 Weeks
Acromegaly symptoms are sweating, snoring, joint pain, headache and fatigue. Each symptom was scored as -2 = 'always', -1 = 'most of the time', 0 = 'sometimes', 1 = 'rarely and 2 = 'never'. The total score was used to evaluate symptom control in each patient at Week 0 and Week 24/Termination. The total worst score is -10 and best score is 10.
Total Health Care Professional Convenience Questionnaire Score at Week 24/Termination
Time frame · 24 weeks
Healthcare professional convenience questionnaires are: Confident the Subject Properly Administering the Injection; Subject Complained About Pain When Administering the Injection; Subject Appreciated the Option of Self-Injection at Home. Each Healthcare professional convenience questionnaire was scored -2, -1, 0, 1 and 2; from most negative to most positive response. A total score across all questions was calculated and was used to evaluate the convenience. The worst total score is -6 and best total score is 6.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * The subject must give signed informed consent before any study-related activities. * The partner, if applicable, must give signed informed consent before administration of Somatuline Autogel. * The subject must be able to understand the protocol requirements. * The subject must have a clinical diagnosis of acromegaly due to pituitary tumor. * The subject must be treated with a long-acting somatostatin analogue with or without a dopamine agonist and have been on the current medical regimen for at least 3 months prior to screening and have IGF-1 levels no higher than 10% above the upper limit of the normal range for age and gender at the screening visit or be somatostatin analogue naïve (if the subject is treated with a dopamine agonist he/she must have been on the current dose for at least 3 months prior to screening). * Subjects who are treated with a dopamine agonist have to stay on their current dose for the duration of the study. * Switch subjects must have had their last pre-study routine clinical treatment with Sandostatin LAR between 28 and 35 days before Visit 2 (enrollment). * The subject must be able to store the study medication in a refrigerator in his/her own or his/her partner's home. * The subject must be ≥18 years of age. * Female subjects of childbearing potential must use adequate contraception. * Female subjects of childbearing potential who are taking oral contraceptives must agree to stay on their current contraceptive dose for the duration of the study. * The partner, if applicable, must be ≥18 years of age. Exclusion Criteria: * The subject has had pituitary surgery (adenomectomy) within 3 months prior to screening. * The subject has received pituitary radiotherapy within 3 years prior to screening. * The subject has received a GH receptor antagonist within 6 months prior to screening. * The subject is currently on a higher dose of Sandostatin LAR than 30mg q28d * The subject is pregnant or breastfeeding. * The subject has clinically significant renal or hepatic abnormalities. * The subject has a symptomatic, untreated biliary lithiasis. * The subject has uncontrolled diabetes or thyroid disease. * The subject has a known hypersensitivity to any of the test materials or related compounds. * The subject is unable or unwilling to comply with the protocol. * The subject has received any investigational drug within 30 days prior to screening. * The subject has participated in a medical device study within 30 days prior to screening. * The subject has previously participated in this study.
Study locations
13 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Diabetes and Endocrine Associates
La Mesa, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Denver VA Medical Center
Denver, Colorado, United States
Northwestern University The Feinberg School of Medicine
Chicago, Illinois, United States
Johns Hopkins University
Baltimore, Maryland, United States
Massachussetts General Hospital
Boston, Massachusetts, United States
NYU School of Medicine
New York, New York, United States
Columbia University
New York, New York, United States
Sisters of Charity Hospital, Buffalo
Williamsville, New York, United States
Oregon Health and Science University
Portland, Oregon, United States
Research Institute of Dallas
Dallas, Texas, United States
Baylor College of Medicine
Houston, Texas, United States
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Related trials
More studies on Lanreotide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
Camurus AB · Gastro-enteropancreatic Neuroendocrine Tumor
Phase 3
Active, not recruiting
332
2026-07
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 3
Recruiting
141
2026-06
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
West China Hospital · Neuroendocrine Tumors
Not applicable
Active, not recruiting
500
2026-04
Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
National Health Research Institutes, Taiwan · Neuroendocrine Tumors,Gastroenteropancreatic
Phase 1 / Phase 2
Recruiting
49
2026-04
Lanreotide In Polycystic Kidney Disease Study
Assistance Publique - Hôpitaux de Paris · Autosomal Dominant Polycystic Kidney Disease (ADPKD
Phase 3
Completed
159
2026-04
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network · Pancreatic Carcinoma · Pancreatic Neoplasm
Phase 3
Recruiting
274
2026-03
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RayzeBio, Inc. · GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor
Phase 3
Recruiting
338
2026-03
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc. · Carcinoid Syndrome · Carcinoid
Phase 2
Completed
36
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.